1. Impact of vaccine platform and BCG vaccination on antibody responses to COVID-19 vaccination
- Author
-
Nicole L. Messina, Mariana G. Sperotto, Marco A. M. Puga, Patricia V. da Silva, Roberto D. de Oliveira, Cecilia L. Moore, Laure F. Pittet, Tenaya Jamieson, Margareth Dalcolmo, Glauce dos Santos, Bruno Jardim, Marcus V. G. Lacerda, Nigel Curtis, and Julio Croda
- Subjects
vaccine ,COVID-19 ,antibody ,ChAdOx1-S ,CoronaVac ,BCG ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Multiple factors, including vaccine platform and prior vaccinations, influence vaccine responses. We compared antibody responses to CoronaVac (Sinovac) and ChAdOx1-S (AstraZeneca-Oxford) vaccination in 874 healthcare workers in Brazil. As participants were randomised to BCG vaccination or placebo in the preceding 0-6 months as part of the BCG vaccination to reduce the impact of COVID-19 in healthcare workers (BRACE) trial, we also investigated the influence of recent BCG vaccination on antibody responses to these COVID-19 vaccines. Twenty-eight days after the second dose of each vaccine, ChAdOx1-S induced a stronger anti-spike IgG response than CoronaVac vaccination. Recent BCG vaccination did not impact IgG antibody responses to ChAdOx1-S or CoronaVac.
- Published
- 2023
- Full Text
- View/download PDF